Study reveals schizophrenia patients find little support from mental health staff in reducing side effects-heavy drugs.
Antidepressant users share their frustrations towards a healthcare system that overprescribes but is ill-equipped to support with discontinuation and withdrawal symptoms.
Study reveals most patients are dissatisfied with prescribers' support when discontinuing antidepressants.
Paroxetine, SNRIs, and MAOIs were associated with the highest risk of withdrawal, as was long duration of use and whether the person experienced withdrawal in the past.
Researchers argue that common study methods for psychiatric drugs may inadvertently minimize withdrawal effects and inflate drug efficacy.
Current long-term users of benzodiazepines and Z-drugs identify barriers and facilitators for discontinuation.
New guidance on how to taper and discontinue from psychiatric drugs from leading researchers Mark Horowitz and David Taylor.
Research suggests that slowly tapering off an antipsychotic reduces the risk of withdrawal psychosis compared to abrupt discontinuation.
A new study investigates how antidepressant withdrawal effects often get confounded with depression relapse in clinical trials.
“Short and simple psychological programs can prevent people from relapsing when they stop their antidepressants.”
After 15 years, the founder of SurvivingAntidepressants.org, Adele Framer, shares what she has learned about the science of withdrawing from psychiatric drugs.
Adverse physiological symptoms of antidepressant withdrawal are regularly mistaken to be other problems to the detriment of the patient.
Online communities are stepping in to help people facing withdrawal effects amass information and receive support for their withdrawal experiences.
Protracted Withdrawal Syndrome characterized by long-term adverse experiences after coming off of antidepressants.
A new study looks at how online communities provide information and support for patients experiencing psychiatric drug withdrawal.
Patient advocates join with researchers and service users to present first-hand experiences of antidepressant withdrawal.
“My life was very, very good.” That’s how Michael sums up how things were for him—prior to his suffering from devastating withdrawal effects after discontinuing GlaxoSmithKline’s blockbuster drug Paxil.
The FDA has finally acknowledged the adverse effects of benzodiazepines, the dangers of withdrawal, and that the current packaging does not sufficiently warn of these harms.
Royal College of Psychiatrists’ former president demands support for patients coming off antidepressants.
A new study by Peter Groot and Jim van Os investigated whether tapering strips can help people stop using antidepressants.
An article in JAMA Psychiatry advises very slow tapering for best results when discontinuing antipsychotic drugs.
A new review of strategies to support both patients and practitioners through the process of discontinuing antidepressants.
New strategies for tapering psychiatric drugs achieved by acknowledging withdrawal symptoms and valuing service-users’ first-hand knowledge.
Researchers find that most psychiatric drugs cause severe withdrawal despite attempt s to gradually decrease the dosage.
Neuropsychological assessments reveal the cognitive, occupational, and social impact of polypharmacy in psychiatry.